Alliqua merges with Adynxx to create a new company to promote brivoligide for the reduction of long term pain relief and the reduction of opioids.

Alliqua BioMedical, Inc. and Adynxx, Inc., a privately held biopharmaceutical company, announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua�s outstanding common stock on a fully-diluted basis. The proposed merger will create a public clinical-stage pharmaceutical company focused on developing a platform of first-in-class, disease-modifying, non-opioid therapies for the treatment of pain. Adynxx�s lead product candidate, brivoligide for the reduction of postoperative pain, is intended to provide long-term pain relief and reduced opioid usage with a single administration at the time of surgery in a group of patients with a greater risk of experiencing increased and prolonged pain following surgery.